// App-Quantinova.ai

: Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed By Nivolumab Consolidation in Patients with Limited Stage Hodgkin Lymphoma

Researchers

Presenter

  • Steven I. Park

Principal Investigators

  • Stephen M. Ansell

  • Sharmila Giri

  • Jakub Svoboda

  • Stephen D Smith

  • Tatyana Feldman

  • Elizabeth L. Budde

  • Andrew J Ness

  • Yunsik Choi

  • Philip J Bierman

  • Hun Ju Lee

Medical Centers

  • Division of Hematology, Mayo Clinic, ROCHESTER, MN

  • Division of Medical Oncology, Fred Hutchinson Cancer Center/University of Washington, Seattle, WA

  • T Cell Therapeutics Research Laboratory, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

  • Business School, Meredith College, Raleigh, NC

  • Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE

  • Division of Hematology and Oncology, Hackensack University Medical Center, Hackensack, NJ

  • Department of Medicine, Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Levine Cancer Institute, Department of Hematologic Oncology and Blood Disorders, Wake Forest University, Atrium Health, Charlotte, NC

  • Department Quantitative Health Sciences, Mayo Clinic, Rochester, MN

  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • brentuximab vedotin

  • Adcetris

  • Nivolumab

  • Filgrastim

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved